A number of investment brokers have recently updated their price targets on shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/06/2016 – ARIAD Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Cowen. They now have a USD 10 price target on the stock.

04/19/2016 – ARIAD Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at JMP Securities. They now have a USD 9 price target on the stock.

03/09/2016 – ARIAD Pharmaceuticals, Inc. had its “market outperform” rating reiterated by analysts at JP Morgan. They now have a USD 9 price target on the stock.

01/19/2016 – Barclays began new coverage on ARIAD Pharmaceuticals, Inc. giving the company a “underweight” rating. They now have a USD 6 price target on the stock.

07/20/2015 – ARIAD Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 7 price target on the stock.

06/25/2015 – ARIAD Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at William Blair. They now have a USD 11 price target on the stock.

06/03/2015 – ARIAD Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright.

05/15/2015 – ARIAD Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 14 price target on the stock.

05/14/2015 – ARIAD Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus.

05/08/2015 – ARIAD Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at UBS. They now have a USD 9 price target on the stock.

12/11/2014 – ARIAD Pharmaceuticals, Inc. was downgraded to “underperform” by analysts at Credit Suisse. They now have a USD 6 price target on the stock.

11/06/2014 – ARIAD Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Chardan Capital.

08/08/2014 – ARIAD Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at Citigroup. They now have a USD 5 price target on the stock.

08/07/2014 – ARIAD Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 12 price target on the stock.

02/27/2014 – ARIAD Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 9 price target on the stock.

The share price of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) was up +3.71% during the last day of trading, with a day high of 7.07. 2833750 shares were traded during the last session.

The stock’s 50 day moving average is 6.76 and its 200 day moving average is 6.19. The stock’s market capitalization is 1.32B. ARIAD Pharmaceuticals, Inc. has a 52-week low of 4.37 and a 52-week high of 10.07.

View other investors thoughts on ARIAD Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.